• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA orders Philips Respironics to improve communications over ventilator recall

FDA orders Philips Respironics to improve communications over ventilator recall

March 11, 2022 By Sean Whooley

PhilipsThe FDA issued a notification order alerting Philips (NYSE:PHG) that its notification efforts on the recall of its ventilators have been inadequate to date.

Philips Respironics last year recalled millions of specific ventilators, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) machines due to polyester-based polyurethane (PE-PUR) sound abatement foam breaking down. Foam particles could enter a device’s air pathway, causing a range of potential health problems and toxic, carcinogenic effects for the user.

Philips said last summer that it was no longer taking orders of sleep therapy systems as it handled the recall, which knocked it out of the sleep therapy market for at least a year. FDA has classified the recalls as Class I, the most serious kind.

In a news release, the FDA confirmed that it will require Philips to do a better job of notifying patients and others of its recall after what the agency labeled as inadequate efforts so far. That includes notifying all device users, durable medical equipment (DME) suppliers, distributors, retailers and health care providers who prescribe the products about the recall and the health risks posed by the foam used in the recalled products.

Additionally, the FDA directed Philips to maintain language to patients regarding the risk of using ozone cleaners on the recalled device on their main webpage for the recall and to provide instructions for device users to register their devices through the Philips website.

“The FDA has heard the frustration expressed by patients and durable medical equipment suppliers who are unaware of the recall and have received insufficient information on their next steps regarding the recall process,” Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, said in the release. “Taking this action today enables the FDA to mandate that Philips Respironics improve its communication about the recall and the serious risk posed by the foam used in the recalled products with patients and the public and to ensure that individuals who rely on these essential devices are receiving the important information they need from the company.”

In addition to the actions recommended, the FDA suggested additional measures for Philips to better communicate with the public on the recall, including monthly updates to device users registered on Philips’ website. Those updates would include information on the expected time for replacement and the current rate of replacement.

The FDA said it has worked with Philips across several fronts regarding the effectiveness of the company’s communications with the public surrounding the recall. The agency said it “is likely a significant portion of patients and consumers using the recalled products are unaware of the health risks presented by those products.” The order directs Philips to provide the notification described in the order within 45 days of its issuance.

Philips issued a notification in response, confirming its efforts to monitor recall awareness for affected users.

“Philips Respironics is working cooperatively with the [FDA] to further increase awareness for patients, consumers, and healthcare providers of the recall,” the company wrote in the update. “Based on feedback from the FDA, Philips Respironics will be working with its DME customers to allow the company to directly contact those patients and other end-users that may not yet have received notice of the recall.”

The company said it has shipped a total of more than 650,000 replacement devices to U.S. customers and plans to complete the repair and replacement program in Q4 2022.

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Recalls, Regulatory/Compliance, Respiratory Tagged With: FDA, Philips, Philips Respironics

In case you missed it

  • Exactech announces breakthrough nod for JointMedica’s hip resurfacing system
  • Accuray names Sandeep Chalke as chief commercial officer
  • Labcorp launches at-home collection device for diabetes risk testing
  • Medtronic’s renal denervation system demonstrates better blood pressure control, time in range
  • iRhythm stays silent on federal grand jury subpoenas
  • Texas power grid struggles a year after cold stopped semiconductor plants
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance

RSS From Medical Design & Outsourcing

  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS